Safety of Tofacitinib vs Biologics in PsA: One Risk Differs Tofacitinib shows safety comparable with biologics for PsA regarding serious infections, myocardial infarction or stroke, and malignancy but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results